Compare ENGN & BSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ENGN | BSBK |
|---|---|---|
| Founded | 1999 | 1893 |
| Country | Canada | United States |
| Employees | 82 | N/A |
| Industry | | Banks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 108.0M |
| IPO Year | N/A | 2019 |
| Metric | ENGN | BSBK |
|---|---|---|
| Price | $1.67 | $8.92 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $21.08 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 22.4K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 200.00 |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $149.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $7.20 |
| 52 Week High | $12.25 | $9.49 |
| Indicator | ENGN | BSBK |
|---|---|---|
| Relative Strength Index (RSI) | 29.71 | 66.61 |
| Support Level | $1.40 | $8.19 |
| Resistance Level | $1.87 | $9.44 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | 0.21 | 0.06 |
| Stochastic Oscillator | 39.71 | 71.83 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from, customers in New Jersey. The Company operates one reportable segment of business, retail banking. Through its community banking segment, the Company provides a broad range of retail and commercial banking services.